Medivir takes $45 million up front for Xerese and hands over full US rights to Meda
This article was originally published in Scrip
Executive Summary
Medivir has renegotiated the terms of its commercial partnership with Meda for the cold sore (recurrent herpes labialis) treatment Xerese (5% aciclovir plus 1% hydrocortisone). It will now receive a $45 million payment from Meda in return for transferring all rights to the product in the US, Canada and Mexico. Meda launched the product in the US in February this year where it is available on prescription and Medivir currently receives a double digit royalty on Meda's sales in this market. Their collaboration on the product was signed in February last year.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.